Fremanezumab

Drug Profile

Fremanezumab

Alternative Names: Anti-calcitonin gene-related peptide monoclonal antibody; Anti-CGRP monoclonal antibody; LBR 101; PF 04427429; PF 4427429; RN-307; TEV-48125

Latest Information Update: 19 Jun 2017

Price : $50

At a glance

  • Originator Rinat Neuroscience
  • Developer Rinat Neuroscience; Teva Pharmaceutical Industries
  • Class Antimigraines; Monoclonal antibodies
  • Mechanism of Action Calcitonin gene-related peptide receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cluster headache; Migraine

Most Recent Events

  • 07 Jun 2017 Teva Pharmaceutical Industries announces intention to submit BLA to the US FDA for Migraine in the second half on 2017
  • 07 Jun 2017 Efficacy and adverse event data from the phase III HALO-EM trial in Migraine released by Teva Pharmaceutical Industries
  • 01 Jun 2017 Adverse events and efficacy data from a phase III trial in Migraine (Prevention) released by Teva Pharmaceutical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top